September 25 Evening of the Shanghai SSE Announcement Express (updated)

Securities Times Network (www.stcn.com) September 25 Gold Yu Group and the French poetry China signed Technology and Trademark license Agreement Jinyu Group (600201) September 25 Night Notice, the company's wholly-owned subsidiary Jinyu Pauling Bio-Pharmaceutical Co., Ltd. ("Jinyu Pauling" ) in June 2013, with the French poetic Chinese Animal Health Company (Ceva Santéanimale S.A) ("Shi Hua Company") signed the "Joint Venture framework Agreement". To expedite the process of cooperation between the two sides, simplified cooperation and approval procedures, the two sides recently signed the "Technology and Trademark License Agreement", the abolition of the original intention to set up a joint venture, by the Jinyu Pauling Direct purchase of the company's cattle and goat brucellosis vaccine production Technology and trademark licensing, solely responsible for production and sales in China. Financial profit PO, current savings rate promotion 1000% Pauling will deliver to Jinyu the Brucellamelitensis Rev. 1 Eye-Drops vaccine (Rev. 1) and Brucellaabortus S-19 Eye vaccine (B 19 products related to biological materials and technology, and grant the above technology-related exclusive license, at the same time to Jinyu Pauling license trademark rights, licensed trademarks can be used Yu Jinyu to produce and sell the Rev 1 and B 192 kinds of vaccines. Jinyu Pauling to the company to pay the licensing fees, including entry fees, phased fees and licensing fees. Of these, the entry fee is € 350,000. In terms of stage expenses, Jinyu Pauling paid 250,000 euros to the company after obtaining the approval of Rev. 1, and paid 250,000 euros to the company after obtaining the approval for B 19. With regard to Rev 1 's license fee, Jinyu Pauling should pay 0.02 euros per toufen for the production and sales of Rev 1 in China as a licence fee. From the second to sixth 12-month period from the date when Jinyu Pauling began selling the product in China, the annual minimum amount for the license fee should be € 300,000, and from the seventh to 11th 12-month period, the minimum annual amount for the licence fee should be 200,000 euros. If the annual sales of the product is less than 10 million toufen, the minimum amount of the license fee shall be determined by mutual consultation. For a license fee of B 19, Jinyu Pauling shall pay the license fee to the company in accordance with 12% of its net sales of B 19 in China. In addition, in order to ensure the smooth realization of Jinyu Pauling production and sales, the company should be in technical assistance to Jinyu Pauling to provide compliance assistance and technical services, Jinyu Pauling to the company to pay a service fee of 402,000 euros. Gold Yu Group said that China's cattle and sheep breeding volume in the world's first, Jinyu Pauling through the introduction of this technology, to help achieve domestic production of brucella vaccine technology upgrades, and to promote the company's new business expansion and development of products. The application of the bonds issued by the SFC has been audited by the Securities and Futures Commission (600469) September 25 night notice, China Securities Regulatory Commission issued the Audit committee to the companyThe application for the bond was reviewed. According to the result of the audit, the company's application for issuing corporate bonds was approved. According to the previous announcement, the company intends to issue no more than 900 million yuan corporate bonds, bonds for a period of not more than 5 years (including 5 years), to improve the debt structure, repay the company debt, replenish liquidity. Oriental Venture by major shareholders to reduce the share of the Oriental Venture (600278) September 25 Evening announcement, the company received the company's largest shareholder Oriental International Group Notice, learned that Oriental International Group on September 24, 2013 through the Shanghai Stock exchange of large trading platform to reduce the company shares 5 million shares, Therefore, from August 28, 2013 to September 24, 2013, Oriental International Group through the Shanghai Stock Exchange auction system and the bulk trading platform cumulative reduction of the company's shares have reached 9.4512 million shares, accounting for the company's total equity of 1.81%. After the reduction, Oriental International Group Holdings 369 million shares, accounting for the company's total share capital of 70.62%, remains the company's largest shareholder. Dongfeng Technology Internal Integration East Instrument Auto trade and Shanghai Ke Tai ") absorption merged Shanghai Ke Tai Investment Co., Ltd. (" Shanghai Ke Tai "). After the merger, Shanghai Branch Thai personnel, business, financial and other integrated into the East Instrument automobile trade. East Instrument Auto Trade and Shanghai Branch Thai are Dongfeng Science and technology 100% holding subsidiaries. Dongfeng Technology said that the merger of two subsidiaries would optimize the business structure. Through the company's internal integration, but also to the East Instrument auto trade to get enough financial support, to help achieve the company bigger and stronger car sales and service business long-term development strategy. Dongfeng Technology third quarter net profit 1260% Dongfeng Technology (600081) announced the announcement of performance in the evening of September 25, is expected to achieve the third quarter of 2013 net profit attributable to shareholders of listed companies compared with the same period a year ago, will increase by about 1260%. In the same period last year, the company's ownership of the listed company's shareholders net profit of 2.2306 million yuan. The main reason for the increase in performance was a significant increase in operating performance over a year earlier. The application for Non-public issue of shares of Wisco was approved by the SFC through the September 25 evening announcement of the Securities and Futures Commission issued by the CSRC, and the company's application for Non-public offering of shares was approved. The company will make a separate announcement after receiving the written approval documents from the CSRC.